ATE516305T1 - Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten - Google Patents

Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten

Info

Publication number
ATE516305T1
ATE516305T1 AT05707720T AT05707720T ATE516305T1 AT E516305 T1 ATE516305 T1 AT E516305T1 AT 05707720 T AT05707720 T AT 05707720T AT 05707720 T AT05707720 T AT 05707720T AT E516305 T1 ATE516305 T1 AT E516305T1
Authority
AT
Austria
Prior art keywords
ralpha
agonists
antagonists
specific
binding site
Prior art date
Application number
AT05707720T
Other languages
English (en)
Inventor
Jerome Bernard
Ariane Plet
Yannick Jacques
Catherine Harb
Agnes Quemener
Erwan Mortier
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE516305T1 publication Critical patent/ATE516305T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT05707720T 2004-02-27 2005-02-10 Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten ATE516305T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290542 2004-02-27
PCT/EP2005/002367 WO2005085282A1 (en) 2004-02-27 2005-02-10 Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity

Publications (1)

Publication Number Publication Date
ATE516305T1 true ATE516305T1 (de) 2011-07-15

Family

ID=34917212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05707720T ATE516305T1 (de) 2004-02-27 2005-02-10 Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten

Country Status (6)

Country Link
US (2) US7858081B2 (de)
EP (1) EP1718670B1 (de)
JP (3) JP5744369B2 (de)
AT (1) ATE516305T1 (de)
ES (1) ES2367027T3 (de)
WO (1) WO2005085282A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5744369B2 (ja) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
EP2314621B1 (de) 2004-05-27 2014-03-05 Crucell Holland B.V. Bindungsmoleküle, die zur Neutralisierung des Tollwutvirus fähig sind, sowie deren Verwendungen
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
US8124084B2 (en) 2005-05-17 2012-02-28 University Of Connecticut Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
EP1777294A1 (de) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine
EP2251034B1 (de) 2005-12-02 2018-02-14 Icahn School of Medicine at Mount Sinai Chimäre newcastle disease viren zur präsentation von nicht -nativen oberflächenproteinen und deren verwendung
AU2007207785B2 (en) 2006-01-13 2013-11-14 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL- 15 and IL- 15R-alpha genes for expression in mammalian cells
AU2013273643C1 (en) * 2007-05-11 2016-08-11 Altor Bioscience Corporation Fusion molecules and il-15 variants
CN104109200B (zh) 2007-05-11 2018-03-20 阿尔托生物科学有限公司 融合分子与il‑15变异体
EP2173378B1 (de) 2007-06-27 2014-03-19 Admune Therapeutics LLC Komplexe von il-15 und il-15ralpha und ihre verwendungen
CU23716A1 (es) * 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
EP2464377B1 (de) 2009-08-14 2016-07-27 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Verwendung von il-15 zur erhöhung der thymusleistung und zur behandlung von lymphopenie
WO2011031986A1 (en) 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
AU2010291900A1 (en) * 2009-09-14 2012-03-22 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
EP2911684B1 (de) 2012-10-24 2019-06-19 Novartis Ag Il-15r-alpha-formen, il-15r-alpha-formen exprimierende zellen und therapeutische verwendung von il-15r-alpha und il-15/il-15r-alpha-komplexen
CN111218429A (zh) 2013-03-14 2020-06-02 西奈山伊坎医学院 新城疫病毒及其用途
CN109395064A (zh) 2013-04-19 2019-03-01 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
WO2014207173A1 (en) * 2013-06-27 2014-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
KR102564207B1 (ko) 2013-08-08 2023-08-10 싸이튠 파마 Ｉｌ―１５ 및 ｉｌ―１５ｒ 알파 스시 도메인 기반 모듈로카인
KR102457731B1 (ko) 2013-08-08 2022-10-21 싸이튠 파마 병용 약학 조성물
WO2015048498A2 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
CA2935599A1 (en) 2014-01-08 2015-07-16 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterodimeric protein and uses thereof
KR102407019B1 (ko) 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 결합 방법
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
WO2016018920A1 (en) 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
MX2017004838A (es) * 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
EP3064507A1 (de) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusionsproteine mit einem bindenden Protein und einem Interleukin-15-Polypeptid mit reduzierter Affinität für IL15ra und therapeutische Verwendungen davon
JP2019503348A (ja) * 2015-12-21 2019-02-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3526241A1 (de) * 2016-10-14 2019-08-21 Xencor, Inc. Il15/il15r-heterodimere fc-fusionsproteine
SG11201903306SA (en) 2016-10-21 2019-05-30 Altor Bioscience Corp Multimeric il-15-based molecules
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
WO2018229706A1 (en) * 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
WO2018236890A1 (en) 2017-06-20 2018-12-27 Nantkwest, Inc. COMBINED THERAPY WITH NK-92 CELLS AND IL-15 AGONIST
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
AU2018328209A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
AR114445A1 (es) * 2018-02-26 2020-09-09 Synthorx Inc Conjugados de il-15, y sus usos
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
WO2019204655A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
TW202011984A (zh) * 2018-04-18 2020-04-01 美商山可爾股份有限公司 IL-15/IL-15Rα異二聚體Fc融合蛋白及其用途
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
WO2019246392A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
WO2020077276A2 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
EP3972629A1 (de) 2019-05-20 2022-03-30 Cytune Pharma Il-2/il-15rssy-agonist-dosierschema zur behandlung von krebs oder infektionskrankheiten
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
US20220289838A1 (en) 2019-08-19 2022-09-15 Nantong Yichen Biopharma. Co. Ltd. Immunocytokine, Preparation for the Same, and Uses Thereof
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20210188933A1 (en) * 2019-12-18 2021-06-24 Nantcell, Inc Methods of treating pancytopenia
WO2021142476A1 (en) 2020-01-12 2021-07-15 Dragonfly Therapeutics, Inc. Single-chain polypeptides
CN114380919A (zh) * 2020-10-18 2022-04-22 北京志道生物科技有限公司 经修饰的il-2分子及其用途
WO2022090202A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
AU2021367887A1 (en) 2020-10-26 2023-06-01 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
CN113185600A (zh) * 2021-05-28 2021-07-30 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
AU2022299404A1 (en) 2021-06-23 2023-12-07 Cytune Pharma Interleukin 15 variants
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552303A (en) * 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
ES2243995T3 (es) * 1996-04-26 2005-12-01 Beth Israel Deaconess Medical Center, Inc. Antagonistas de interleucina-15.
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
JP5744369B2 (ja) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体

Also Published As

Publication number Publication date
JP5819281B2 (ja) 2015-11-24
US7858081B2 (en) 2010-12-28
JP5744369B2 (ja) 2015-07-08
US20110158938A1 (en) 2011-06-30
JP2007528726A (ja) 2007-10-18
US9493533B2 (en) 2016-11-15
ES2367027T3 (es) 2011-10-27
EP1718670A1 (de) 2006-11-08
US20080255039A1 (en) 2008-10-16
JP2013081472A (ja) 2013-05-09
EP1718670B1 (de) 2011-07-13
WO2005085282A1 (en) 2005-09-15
JP2015214561A (ja) 2015-12-03

Similar Documents

Publication Publication Date Title
ATE516305T1 (de) Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
ES2171768T3 (es) Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
MY138267A (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
TNSN04001A1 (fr) Association d'un antagoniste des recepteurs d'aldosterone et d'un inhibiteur de hmg-coa- reductase.
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
ATE364618T1 (de) Antikörper gegen das muc18-antigen
MA29663B1 (fr) Modification du facteur fviii en fonction du site
DE69940063D1 (de) Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
MXPA03003902A (es) Polipeptidos de proquineticina, composiciones relacionadas y metodos.
CY1116415T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν l-733060 για χρηση στη θεραπευτικη αγωγη καρκινικων ογκων
BRPI0412537A (pt) antagonista do receptor muscarìnico da acetilcolina
RS89104A (en) Novel antagonists of mcp proteins
CO5460266A1 (es) Novedosos analogos de la somatostatina
DE60236212D1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
TNSN05315A1 (en) Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
DE60135158D1 (de) Antagonisten des ige-rezeptors
DE602004012763D1 (de) Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
CY1108643T1 (el) Κυτταρικη σειρα και χρησεις της
DE60326430D1 (de) Varianten von säugerprolactin
ATE373718T1 (de) 17867, eine menschliche aminopeptidase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties